These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1977180)

  • 1. Dosing regimen differentiates sensitization of locomotion and mouthing to D2 agonist quinpirole.
    Eilam D; Szechtman H
    Pharmacol Biochem Behav; 1990 Aug; 36(4):989-91. PubMed ID: 1977180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole.
    Zhou LW; Qin ZH; Weiss B
    Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism.
    Szechtman H; Talangbayan H; Canaran G; Dai H; Eilam D
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):95-104. PubMed ID: 7862919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of administration of dopamine D2 agonist quinpirole on exploratory locomotion.
    Mogenson GJ; Wu M
    Brain Res; 1991 Jun; 551(1-2):216-20. PubMed ID: 1680523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacological responsiveness to the dopamine agonist quinpirole in normal weanlings and in weanling offspring exposed gestationally to cocaine.
    Moody CA; Frambes NA; Spear LP
    Psychopharmacology (Berl); 1992; 108(3):256-62. PubMed ID: 1355920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats.
    Culver KE; Rosenfeld JM; Szechtman H
    Psychopharmacology (Berl); 2000 Aug; 151(2-3):202-10. PubMed ID: 10972466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinpirole to the accumbens reduces exploratory and amphetamine-elicited locomotion.
    Mogenson GJ; Wu M
    Brain Res Bull; 1991 Nov; 27(5):743-6. PubMed ID: 1684529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM; Marin C; Susel Z; Chase TN
    Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clorgyline-induced switch from locomotion to mouthing in sensitization to the dopamine D2/D3 agonist quinpirole in rats: role of sigma and imidazoline I2 receptors.
    Culver KE; Szechtman H
    Psychopharmacology (Berl); 2003 May; 167(2):211-8. PubMed ID: 12652347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microinjection of the D2 agonist quinpirole into the A10 dopamine region blocks amphetamine-, but not cocaine-stimulated motor activity.
    Steketee JD; Kalivas PW
    J Pharmacol Exp Ther; 1992 May; 261(2):811-8. PubMed ID: 1349649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
    Hu XT; Brooderson RJ; White FJ
    Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effects of chronic treatment with antidepressant drugs and intermittent treatment with a dopamine agonist.
    Papp M; Muscat R; Willner P
    Eur Neuropsychopharmacol; 1992 Jun; 2(2):121-5. PubMed ID: 1353000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphasic effect of D-2 agonist quinpirole on locomotion and movements.
    Eilam D; Szechtman H
    Eur J Pharmacol; 1989 Feb; 161(2-3):151-7. PubMed ID: 2566488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
    Chen JF; Aloyo VJ; Weiss B
    Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole.
    Szechtman H; Dai H; Mustafa S; Einat H; Sullivan RM
    Pharmacol Biochem Behav; 1994 Aug; 48(4):921-8. PubMed ID: 7972297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates.
    Zhang M; Creese I
    Neurosci Lett; 1993 Oct; 161(2):223-6. PubMed ID: 7903803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontogenetic quinpirole treatment induces vertical jumping activity in rats.
    Kostrzewa RM; Guo J; Kostrzewa FP
    Eur J Pharmacol; 1993 Aug; 239(1-3):183-7. PubMed ID: 7901028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations.
    Moody CA; Robinson SR; Spear LP; Smotherman WP
    Pharmacol Biochem Behav; 1993 Apr; 44(4):843-50. PubMed ID: 8097042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of dopamine D2 agonist quinpirole upon the dorsal immobility response in rats.
    Meyer ME; Meyer ME; Potter TJ; Van Hartesveldt C
    Pharmacol Biochem Behav; 1992 Jun; 42(2):257-9. PubMed ID: 1352900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.